- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05494788
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Impact of CardiolRxTM on Recurrent Pericarditis An Open Label Pilot Study (MAvERIC-Pilot Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multi-center, open label Pilot Study. Patients who present with recurrent pericarditis will be screened and informed consent obtained.
Baseline assessments include the following: Clinical assessment, including vital signs, highest NRS pain score within the past 7 days of Day 1, 12-lead ECG; C-SSRS as well as hematology and blood chemistry and a pregnancy test for women with child-bearing potential.
Concomitant medications are recorded and any (S)AEs after informed consent has been obtained.
Study treatment will be initiated in the evening of Day 1, after all baseline assessments are completed.
Oral administration is as follows:
Initial starting dose (Day 1 p.m. dose to Day 3 a.m. dose):
5 mg/kg of body weight CardiolRxTM
- Day 3 p.m. dose to Day 10 a.m. dose: 7.5 mg/kg of body weight CardiolRxTM b.i.d.
- Day 10 p.m. dose to end of treatment period: 10.0 mg/kg of body weight CardiolRxTM b.i.d.
If the next higher dose after each study drug increase is not tolerated, the dose will be reduced to the previous tolerated dose.
Unless contraindicated in the opinion of the investigator, after 8 weeks of treatment, patients will enter an 18-week extension period (EP), in which they continue study treatment while their concomitant medications will be weaned.
Follow-up Procedures Every visit (before the next dose increase) the patient will be re-evaluated. This includes ECG monitoring at approximately 5 hours post-morning dose (Tmax) to surveil for deleterious effects on ECG intervals (particularly the QTc interval) and rhythm.
Drug titration will be dependent on investigator or designate interrogation of the ECGs and the absence of new, clinically significant abnormalities on those ECGs.
Vital signs, concurrent medication and (S)AEs will be recorded at all visits. Blood chemistry including liver function tests, hematology as well as INR assessments will be carried out at selected visits.
Final efficacy assessments will take place after 26 weeks of study treatment and include a clinical assessment, vital signs, pain score NRS, a 12-lead ECG, the C-SSRS, as well as laboratory assessments.
For patients who do not enter the EP, Final assessments will be done after 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Andrea B Parker, PhD
- Phone Number: +1 289 9100862
- Email: andrea.parker@cardiolrx.com
Study Contact Backup
- Name: Andrew Hamer, MD
- Email: andrew.hamer@cardiolrx.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- Pima Heart and Vascular Clinical Research
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Health Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Institute Foundation
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female 18 years of age or older
- Diagnosis of at least two episodes of recurrent pericarditis*,
- At least 1 day with pericarditis pain ≥4 on the 11-point Numerical Rating Scale (NRS) within prior 7 days
One of;
- C-Reactive Protein** (CRP) level ≥1.0 mg/dL within prior 7 days OR
- Evidence of pericardial inflammation assessed by delayed pericardial hyperenhancement on cardiac magnetic resonance imaging (CMR)
- Currently receiving non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination) for treatment of pericarditis in stable doses
- Male patients with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug.
Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] ≥40 mIU/mL [or ≥ 40 IU/L] if less than 2 y postmenopausal) or be surgically sterile.
- Diagnosis of pericarditis according to the 2015 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Pericardial Diseases (Adler et al. 2015):
At least two of:
- Pericarditic chest pain
- Pericardial rub
- New widespread ST-segment elevation or PR-segment depression according to electrocardiogram (ECG) findings
Pericardial effusion (new or worsening)
- Conversion: 1 mg/dL CRP = 10 mg/L hs-CRP
Exclusion Criteria:
- Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); myocarditis
- Estimated glomerular filtration rate (eGFR) <30 mL/min at screening
- Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or ALT or AST >3x ULN plus bilirubin >2x ULN
- Sepsis, defined as documented bacteremia at the time of screening or other documented active infection
- Prior history of sustained ventricular arrhythmia
- History of QT interval prolongation
- QTc interval > 500 msec
- Current participation in any research study involving investigational drugs or device
- Inability or unwillingness to give informed consent
- Ongoing drug or alcohol abuse
- On any cannabinoid during the past month
- Women who are pregnant or breastfeeding
- Current diagnosis of cancer, with the exception of non-melanoma skin cancer
- Any factor, which would make it unlikely that the patient can comply with the study procedures
- Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS), administered at screening
- On digoxin and/or type 1 or 3 antiarrhythmics
On immunosuppressive therapy with any of the following:
- Rilonacept
- Anakinra
- Canakinumab
- Methotrexate
- Azathioprine
- Cyclosporine
- Intravenous immune globulin (IVIG)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CardiolRx
pharmaceutically produced Cannabidiol
|
Pharmaceutically produced Cannabidiol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
11-point NRS pain score
Time Frame: 8 weeks
|
change in patient-reported pericarditis pain using an 11-point NRS from baseline to 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
11-point NRS pain score
Time Frame: 26 weeks
|
Pain score using 11-point NRS after 26 weeks of treatment
|
26 weeks
|
Normalized CRP levels
Time Frame: 26 weeks
|
Percentage of patients with normalized CRP levels at 26 weeks (for patients with CRP ≥1.0 mg/dL at baseline)
|
26 weeks
|
Normalized CRP levels
Time Frame: Over 26 weeks
|
Time to CRP normalization for patients with CRP ≥1.0 mg/dL at baseline
|
Over 26 weeks
|
CRP change from baseline
Time Frame: 26 weeks
|
CRP change from baseline
|
26 weeks
|
pericarditis recurrence during the extension period (EP)
Time Frame: 26 weeks
|
Percentage of patients with pericarditis recurrence during the extension period (EP)
|
26 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Allen Klein, MD, The Cleveland Clinic
Publications and helpful links
General Publications
- Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29. No abstract available.
- Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, Luis SA, Nicholls SJ, Pano A, Wheeler A, Paolini JF; RHAPSODY Investigators. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cardiol 100-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Pericarditis
-
Azienda Ospedaliero, Universitaria Ospedali RiunitiRecruitingRecurrent PericarditisItaly
-
R-Pharm Overseas, Inc.Data Management 365; Keystat, LLCNot yet recruitingRecurrent PericarditisUnited States
-
Hippocration General HospitalNot yet recruitingPericarditis Idiopathic RecurrentGreece
-
R-Pharm International, LLCR-Pharm; Unimed Laboratories CJSC; Data Management 365; Exacte Labs LLCActive, not recruitingIdiopathic Recurrent PericarditisRussian Federation
-
Kiniksa Pharmaceuticals (UK), Ltd.CompletedRecurrent PericarditisUnited States, Israel, Australia, Italy
-
Massimo ImazioCompletedIdiopathic Recurrent PericarditisItaly
-
Kiniksa Pharmaceuticals (UK), Ltd.RecruitingRecurrent PericarditisUnited States
-
Kiniksa Pharmaceuticals (UK), Ltd.Completed
-
King's College LondonGuy's and St Thomas' NHS Foundation Trust; Royal Free Hospital NHS Foundation...RecruitingIdiopathic Recurrent PericarditisUnited Kingdom
-
Mayo ClinicWithdrawn
Clinical Trials on CardiolRx
-
Cardiol Therapeutics Inc.RecruitingAcute MyocarditisUnited States, Israel, Brazil, France, Canada
-
Cardiol Therapeutics Inc.TerminatedCardiovascular Diseases | COVID-19 | Cardiovascular Risk FactorUnited States, Brazil, Mexico